这两种药物组合，让老年雄性小鼠恢复青春，延长寿命70%

Core Insights - The article discusses a study from the University of California, Berkeley, published in the journal Aging, which explores the potential of a combined therapy using oxytocin (OT) and an ALK5 inhibitor (A5i) to extend lifespan and improve health in aging male mice, highlighting sex-specific responses to aging interventions [2][4][6] Group 1: Study Findings - The combined treatment of OT and A5i significantly extended the lifespan of aging male mice by 73% compared to untreated controls, with a median lifespan increase of 14% and notable improvements in agility, endurance, and memory [4] - Treated male mice exhibited a nearly two-thirds lower risk of death at any given time compared to the untreated group [4] - The therapy restored a younger pattern of circulating blood proteins, with long-term benefits in overall protein balance observed only in male mice after four months of treatment [6] Group 2: Gender-Specific Responses - Female mice did not show significant improvements in lifespan or health metrics, although middle-aged females experienced enhanced fertility [6] - The study emphasizes the substantial impact of sex-specific biology on the effectiveness of aging interventions, establishing a useful model for understanding the mechanisms of different therapies across genders [6] Group 3: Future Implications - Oxytocin has already received FDA approval, while the ALK5 inhibitor is currently undergoing clinical trials, suggesting a potential pathway for this combined therapy to be applicable to humans in the future [6] - The significant improvements observed in frail elderly male mice raise hopes for enhancing health and longevity in the elderly population [6]